Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 15/20 | 1.00 |
| ▸ | PKLR | P30613 | 8/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.84 |
| ▸ | MAPT | P10636 | 1/20 | 0.84 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.84 |
| ▸ | NPC1 | O15118 | 2/20 | 0.76 |
| ▸ | RAB9A | P51151 | 2/20 | 0.76 |
| ▸ | USP2 | O75604 | 1/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 3/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | TSHR | P16473 | 2/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1710881 | 1.00 | PKM (1.00) | PKMPKLRKDM4EMEN1KMT2A | |
| SCHEMBL1722416 | 0.88 | PKM (1.00) | PKMPKLRKDM4EMEN1KMT2A | |
| SCHEMBL1722758 | 0.87 | PKM (1.00) | PKMPKLRKDM4EMEN1KMT2A | |
| SCHEMBL4190670 | 0.85 | PKM (0.81) | PKMPKLRKDM4EMEN1KMT2A | |
| SCHEMBL2239660 | 0.85 | PKM (1.00) | PKMPKLRKDM4EMEN1KMT2A | |
| SCHEMBL1725568 | 0.83 | PKM (1.00) | PKMPKLRKDM4EMEN1KMT2A | |
| SCHEMBL12354651 | 0.82 | PKM (1.00) | PKMPKLRKDM4EMEN1KMT2A | |
| SCHEMBL1722721 | 0.82 | PKM (1.00) | PKMPKLRKDM4EKMT2AMAPT | |
| SCHEMBL31315853 | 0.82 | PKM (1.00) | PKMPKLRKDM4EKMT2AMAPT | |
| SCHEMBL4186845 | 0.82 | PKM (0.76) | PKMPKLRKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12599592-B2 | Therapeutic small molecules for treatment of pulmonary hypertension | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-14 | — | — | US | disclosed |
| US-20250288572-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY VASCULAR DISEASE | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2025-09-18 | — | — | US | disclosed |
| US-20230414590-A1 | THERAPEUTIC SMALL MOLECULES FOR TREATMENT OF PULMONARY HYPERTENSION | THE TEXAS A&M UNIVERSITY SYSTEM | 2023-12-28 | — | — | US | disclosed |
| WO-2022103706-A1 | THERAPEUTIC SMALL MOLECULES FOR TREATMENT OF PULMONARY HYPERTENSION | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250288572-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY VASCULAR DISEASE | GLUL, GGT1, GLS | PKM 793/4885PKLR 442/4885KDM4E 1353/4885 |
| US-12599592-B2 | Therapeutic small molecules for treatment of pulmonary hypertension | GSTP1, GSTK1, GSTM1 | PKM 3769/4885PKLR 2994/4885KDM4E 4536/4885 |
| US-20230414590-A1 | THERAPEUTIC SMALL MOLECULES FOR TREATMENT OF PULMONARY HYPERTENSION | GSTP1, GSTK1, GSTM1 | PKM 3515/4885PKLR 2950/4885KDM4E 4282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.